cisplatin,gemcitabine,nivolumab
bms
['gu ', 'mibc', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'bladder']
hcrn gu 16-257: ph ii gem/cis/nivo in mibc w/ selective bladder sparing gem/cis/nivo x4 cycles---&gt;clinical restaging w/ cysto/bx/cyto/mri--&gt;patient choice of rc vs no rc + 8 cycles nivo 43% clinical cr median f/u 30 mo--&gt;24/33 remain rc-free &amp; 2/33 w/ mets
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology